09-28-2023 / Dr. Lumeng Ye, Director of Novel Therapeutic Material Development, R&D Department, GenScript Biotech

With the fast progress and deeper understanding of CAR-T cell therapy, finding a better solution other than lentivirus transduction is more requested, to overcome the functional limitation on random insertion, uncontrolled copy number of CAR insertion and

Learn More

09-20-2023 / Dr. John Zuris, Director of Editing Technologies – Editas Medicine

Join GenScript in this series of webinars, featuring 3 leaders in the life sciences from academia and industry, leveraging the strengths of synthetic biology technologies to develop life-changing therapies.

Learn More

02-22-2023 / Dr. Fan Zhou, PhD, Sr. Scientist of Molecular Biology, GenScript Biotech

Join us in our webinar to learn more how our new miniature circular dsDNA system--GenCircle dsDNA can help you eliminate risks of antibiotic resistant gene and improves the performance in T cell engineering and in vivo expression.

Learn More

03-17-2022 / Join Prof. Dr. John van der Oost

CRISPR-Cas is an adaptive immune system of prokaryotes (bacteria and archaea)

Learn More

10-28-2021 / Dr. Edward Wong, Dr. Leung How Wing

Despite hundreds of off-the-shelf treatments, cancer remains one of the leading cause of death globally

Learn More

09-15-2021 / Dr. Mohamed Fareh, Senior Research Fellow, Peter MacCallum Cancer Centre

The COVID-19 pandemic has emerged as a catastrophic global emergency. The recent dramatic appearance of variants of concern of SARS-coronavirus-2 (SARS-CoV-2) highlights the need for innovative approaches that simultaneously suppress viral replication and

Learn More

05-20-2021 / Rafael Vázquez Manrique, PhD, Biomedicina Molecular, Celular y Genómica, IIS-La Fe, València, Spain

La tecnología de CRISPR ha revolucionado la biotecnología y la biomedicina como nunca antes otra técnica lo había hecho, con quizás pocas excepciones.

Learn More

05-19-2021 / Dr. Lumeng Ye, Senior Scientist R&D department

With the 5th approval on CAR-T therapy (Abecma) by FDA in early 2021, ex vivo engineered T cell therapy was proved as a mainstay in cancer treatment.

Learn More